Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceGlobe Newswire • 22 days agoZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...